Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

The FUTURE trial is a prospective, multicentre, exploratory, open-label phase II platform trial. Its goal is to evaluate the efficacy, feasibility and safety of futibatinib combined with immunotherapeutic, targeted or chemotherapeutic agents in colorectal and other solid tumors and to additionally identify biomarkers that correlate with clinical outcome.

Trial Details

NCT ID
NCT06722183
Phase
PHASE2
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Futibatinib orally administered
  • Tislelizumab (i.v. 200mg)
Locations (sample)
  • Amberg, Germany|49.44287,11.86267
  • Berlin, Germany|52.52437,13.41053
  • Düsseldorf, Germany|51.22319,6.77927
  • Essen, Germany|51.45657,7.01228
  • Frankfurt am Main, Germany|50.11552,8.68417

Key Eligibility Criteria

  • Patient\* provides signed informed consent.
  • Patient is ≥ 18 years at the time of given informed consent.
  • Patient has a histologically proven solid tumor:
  • Specific for FUTURE-001: Histological or cytological confirmation of colorectal adenocarcinoma that is unresectable and/or metastatic with known RA…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →